Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Boston Scientific Q3
Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory approvals on the stock. Click for more on BSX.
Boston Scientific Q3 Earnings Preview
In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration
Boston Scientific Corporation (NYSE:BSX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 23, 2024 Boston Scientific Corporation beats earnings expectations. Reported EPS is $0.63, expectations were $0.588. Operator: Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call.
15h
Boston Scientific price target raised to $98 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $98 from $95 and keeps an Outperform rating on the shares. The ...
1d
Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the ...
Yahoo Finance
1d
Boston Scientific Corp (BSX) Q3 2024 Earnings Call Highlights: Robust Growth and Strategic ...
Neurology Sales Growth: 10% in
Q3
2024. Endoscopy Sales Growth: 7% organically in
Q3
2024.
Boston
Scientific
Corp ...
19h
Boston Scientific price target raised to $98 from $87 at Wells Fargo
Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The ...
1d
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback